Zelira Therapeutics Limited
ZLDAF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $5 | $4 | $15 | $8 |
| - Cash | $0 | $1 | $0 | $3 |
| + Debt | $2 | $6 | $0 | $1 |
| Enterprise Value | $7 | $9 | $15 | $6 |
| Revenue | $0 | $0 | $0 | $2 |
| % Growth | -99.3% | -68.5% | -80.5% | – |
| Gross Profit | -$1 | $0 | -$3 | -$6 |
| % Margin | -122,400.2% | 10.8% | -1,068% | -371% |
| EBITDA | -$4 | -$36 | -$7 | -$12 |
| % Margin | -617,481.4% | -37,409.9% | -2,238.4% | -771.5% |
| Net Income | -$4 | -$37 | -$6 | -$12 |
| % Margin | -553,029.3% | -38,513% | -1,850.8% | -775.4% |
| EPS Diluted | -0.32 | -3.22 | -0.55 | -1.49 |
| % Growth | 90.1% | -485.5% | 63.1% | – |
| Operating Cash Flow | -$5 | -$4 | -$7 | -$9 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5 | -$4 | -$7 | -$9 |